David Macdonald

Encouraging one-year data from Foldax validating the performance and safety of its polymer mitral valve. A strong milestone as the company moves toward broader adoption.

8

Novartis Extends Its SMA Bet: FDA Approval of Itvisma Puts One-Time Gene Therapy in the Spotlight -( $NVS $IBB $XBI ) #Novartis #Itvisma #SMA #SpinalMuscularAtrophy #GeneTherapy #Biotech #FDAApproval #RareDisease #NeuroScience #PharmaNews #DrugApproval #HealthcareInnovation #OneTimeTherapy #SMN1 #MotorNeurons #Biopharma #HealthcareInvesting #WallStreet #MedicalBreakthrough #LifeSciences

2

Clinical precision matters in metabolic medicine. We partner with licensed providers to implement structured GLP programs backed by oversight, compliance alignment, and operational clarity. Designed for sustainable practice growth. #LongevityHealth #GLP1Therapy #GLP2Health #TRT #PeptideTherapy #HormoneOptimization #AntiAgingMedicine #WeightLossClinic #MetabolicHealth #ClinicGrowthStrategies #FunctionalMedicine #IntegrativeMedicine #Telemedicine #MensHealth #WellnessClinics #MedSpas #LongevityMedicine #HormoneHealth #MedicalWeightLoss #AestheticMedicine #HealthOptimization #AgeManagement #ChronicDiseaseManagement #HealthyAging #PreventiveCare #PatientCareExcellence #HealthcareProviders #MedicalInnovation #PhysicianNetwork #WellnessRevolution

2

Great news out of ShiraTronics, Inc.! The company's continuous neuromodulation system for the treatment of chronic migraine demonstrated a >50% reduction in monthly headache days (MHDs) in its pilot study, from 20 MHDs to 10 MHDs across 12 months. An amazing non-therapeutic option for the huge % of chronic migraine patients who aren't getting what they need from today's therapeutics.

37

Author Capital Partners Announces Milestone Transaction for Its Laboratory Diagnostics Platform We are thrilled to publicly announce that Author Capital Partners—in partnership with industry veteran Christopher Howlett—completed a strategic transaction involving key assets for our laboratory testing and diagnostics platform, Vanta Diagnostics, building on an acquisition platform launched last year. This milestone expands our footprint in the essential healthcare services sector and reflects our continued commitment to high-quality diagnostic solutions. Vanta Diagnostics is a national laboratory services platform, delivering high-quality molecular diagnostics and anatomical pathology solutions across 45 states. With an expanded suite of tests—including Wound-ID™, Urine-ID™, Derm-ID™, Pharmacogenetics, and more—we are positioned to support healthcare providers and patients with rapid, reliable diagnostic results. This investment underscores our conviction in the resilience and strategic importance of diagnostic testing within the broader healthcare ecosystem. “We see tremendous opportunity for innovation in precision medicine to expand access and improve patient care. With a best-in-class leadership team in place, we’re well positioned to scale Vanta and unlock the platform’s full potential,” said Duane Jackson, Managing Partner at Author Capital. A special thank you to the Vanta Diagnostics team, all of our partners and advisors, for their commitment and collaboration to the platform. Read the full press release here: https://lnkd.in/gKPBbXAK #Healthcare #HealthcareServices #Diagnostics #AuthorCapital #VantaDiagnostics

18

News from our portfolio company NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana The Indianapolis facility would serve as Exo-Top’s U.S. manufacturing base, transferring NurExone’s proprietary exosome production process into the American market. The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics. https://lnkd.in/dFfbhGR6

21

✋ It wasn't us - honest truth! It was not by AMS's design or request that an article (p16) that promotes a legacy technology for removing carcinogenic hexavalent chromium but that includes both an image of the trucks that would be required to transport weekly thousands of gallons toxic waste from dozens of local communities to specialized treatment sites and also a 'health warning' from Ecolab that the technology may also generate radioactive waste was placed alongside a fact-based article (page 19) that compares competing treatment technologies. That article systematically addresses why these legacy technologies are not fit for pupose. This also calls into serious question why some leading consulting engineers continue to promote these legacy technologies rather than offering Californian communities the option of an approved and proven solution that has a 40% lower lifetime cost. Thank you CA-NV AWWA for giving us a voice to address this situation which risks imposing unacceptable and avoidable costs on 5 million Californian consumers, many of whom live in underserved communities and who depend on water contaminated by hexavalent chromium. #gatekeepers #barrierstoinnovation #safedrinkingwater https://lnkd.in/gdr_Xjub

15

Hemostemix’s Florida expansion accelerates regenerative access under SB 1768. Through its “Boots on the Ground” initiative, Hemostemix is empowering physicians statewide to provide compassionate, compliant access to ACP-01. An autologous (patient’s own) cell therapy for CLTI pain and wound healing. Florida’s new SB 1768 law opens a pathway for licensed physicians to deliver unapproved stem-cell-based therapies for pain and wound care under strict safety and consent guidelines. “SB 1768 beacons compassionate innovation,” said Thomas Smeenk, CEO, Hemostemix Inc. “Our focus is ensuring ACP-01 can be delivered safely, effectively, and ethically — transforming lives while upholding regulatory integrity.” 🔗 Learn more: https://lnkd.in/gFbyvBWA #Hemostemix #RegenerativeMedicine #VascularHealth #LimbSalvage #StemCellTherapy #SB1768 #Biotech #FloridaHealthcare

12

Mary Wheeler: General Partner at Biorock Ventures shares insights on key steps for securing funding for drug development startups. Focusing on having a clear product, patient group, and a robust plan for demonstrating differentiation. Avoiding getting lost in science and focusing on the basics ensures success. #DrugDevelopment #StartupFunding #Biotech #Pharmaceuticals #DrugDiscovery #VentureCapital #Innovation #Science #Healthcare #Investment

2

Incredibly proud to officially launch Sentinel BioTherapeutics — the first clinical-stage company from RBL LLC, our venture creation studio focused on advanced therapies. Sentinel’s mission is deeply personal and scientifically ambitious: to enable localized immune priming in cancer types where systemic immunotherapies have fallen short. Our lead program, SENT001, is already showing promise in platinum-resistant ovarian cancer — and this is just the beginning. Grateful to be building this with the phenomenal teams at RBL and Sentinel. More to come. Omid Veiseh Paul W., Heidi Hagen, Ravi Ghanta, Amir Jazaeri, Zelanna Goldberg, M.D., M.A.S. Ryan N., Samira Aghlara-Fotovat, David Aubuchon, Lori Kelley

114

14 Comments